Tuesday, September 16th, 2025

“Food Empire Holdings Ltd.: Continued Growth Amidst Rising Coffee Prices”

Food Empire Holdings Ltd. Continues Strong Growth Amidst Rising Coffee Prices

March 17, 2025 | KGI Securities (Singapore) Pte. Ltd.

Continued Strong Growth in South-East Asia and South Asia

Food Empire Holdings saw a sustained increase in sales across its core markets in FY24, showcasing a resilient consumer demand for the company’s products, which saw volume growth YoY, especially in the Southeast Asia and South Asia regions. The group continues to reap the benefits of its brand-building efforts in Vietnam, increasing its market share across the Vietnamese market. Demand for the group’s products in South Asia also remains strong amidst a coffee consumption boom in the region.

Significantly Expanding Production Capabilities Across Asia

In Malaysia, a non-dairy creamer facility expansion was completed in 2Q2024, with full utilization expected within three years, and a snack facility expansion is slated for completion by 1Q2025 with production starting in 2Q2025, substantially increasing snack output. Additionally, a new coffee-mix production facility in Kazakhstan, the company’s first in Central Asia, is under construction and will be operational by the end of 2025, boosting coffee-mix capacity by approximately 15%.

Increased Dividends for Third Consecutive Year

The Board proposes a total dividend of 8.0 Singapore cents per ordinary share comprising the first and final dividend of 6.0 Singapore cents and a special dividend of 2.0 Singapore cents. This is the third consecutive year of an increase in dividends (excluding special dividends).

Navigating Headwinds with Robust Demand

While the group continues to face headwinds such as higher coffee prices resulting in price disruptions, as well as a strong US dollar, demand continues to remain robust for the group’s products. The company is optimistic about the group’s business going forward and maintains an OUTPERFORM recommendation with an increased target price of S\$1.40.

Financials and Key Operating Statistics

Food Empire Holdings reported higher revenue of US\$476.3mn for FY24, up 11.9% YoY, compared to US\$425.7mn in FY23, led by strong growth in its South-East Asia and South Asia market, which saw a growth of 27.3% and 24.9% respectively. However, the company reported a decrease in net profit after tax by 6.4%, from US\$56.5mn in FY23 to US\$52.9mn in FY24 due to higher ingredient prices, as well as continued strong market investments in the company’s Southeast Asia markets.

Valuation and Recommendation

The analyst maintains an OUTPERFORM recommendation and increases the target price to S\$1.40, based on a blended valuation of Discounted Cash Flow (DCF) and comparable Multiples Valuation. The analyst anticipates demand to remain healthy across key markets, and the company will enjoy continued growth in FY25. The company’s expansion plans are expected to increase its production capabilities and also drive higher sales.

Sumber Alfaria Trijaya: Expanding Store Network and Margins in Indonesia’s Convenience Store Market

Comprehensive Financial Analysis of Sumber Alfaria Trijaya Comprehensive Financial Analysis of Sumber Alfaria Trijaya Date of Report: Wednesday, 04 December 2024 Broker Name: UOB Kay Hian Introduction to Sumber Alfaria Trijaya Sumber Alfaria Trijaya,...

Indonesia Consumer Outlook 2025: Navigating Wage Hikes and Economic Challenges

Indonesia Consumer Sector 2025: Comprehensive Company Analysis Indonesia Consumer Sector 2025: Comprehensive Company Analysis Broker Name: PT Maybank Sekuritas Indonesia Date of Report: January 2, 2025 Overview of Indonesia’s Consumer Sector in 2025 The...

Innovent Biologics (1801 HK): Mazdutide Launch Positions Company as Major Player in China’s Weight Management Market – Strong Growth Forecast for 2025 and Beyond

UOB Kay Hian Date of Report: Monday, 14 July 2025 Innovent Biologics: Poised to Dominate China’s Booming Weight Management Market with Breakthrough Mazdutide Launch Innovent Biologics at a Glance Innovent Biologics, Inc. (HKEX: 1801...